Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results

被引：0
|
作者：
Wuerstlein, R. [1 ]
Grischke, E. M. [2 ]
Gluz, O. [3 ]
Kates, R. [3 ]
Persoon, M. [4 ]
Thill, M. [5 ]
Hasmueller, S. [6 ]
Knauer, M. [7 ]
Pusch, R. [8 ]
Harbeck, N. [1 ,3 ]
机构：
[1] Univ Munich, Breast Ctr, Munich, Germany
[2] Univ Tubingen Hosp, Breast Canc Ctr, Tubingen, Germany
[3] WSG, Monchengladbach, Germany
[4] Agendia, Amsterdam, Netherlands
[5] Agaples Markus Hosp, Frankfurt, Germany
[6] Ebersberg Clin, Ebersberg, Germany
[7] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland
[8] Int Med IV Clin Wels Grieskirchen, Wels Grieskirchen, Austria
来源：
BREAST | 2017年 / 32卷
关键词：
D O I：
10.1016/S0960-9776(17)30341-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P255
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results
    Wurstlein, R.
    Gluz, O.
    Grischke, E. M.
    Kates, R. E.
    Thill, M.
    Hasmueller, S.
    Knauer, M.
    Pusch, R.
    Harbeck, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 6 - 6
  • [2] Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
    Wuerstlein, R.
    Kates, R.
    Gluz, O.
    Grischke, E. M.
    Schem, C.
    Thill, M.
    Hasmueller, S.
    Koehler, A.
    Otremba, B.
    Griesinger, F.
    Schindlbeck, C.
    Trojan, A.
    Otto, F.
    Knauer, M.
    Pusch, R.
    Harbeck, N.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 389 - 399
  • [3] Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
    R. Wuerstlein
    R. Kates
    O. Gluz
    E. M. Grischke
    C. Schem
    M. Thill
    S. Hasmueller
    A. Köhler
    B. Otremba
    F. Griesinger
    C. Schindlbeck
    A. Trojan
    F. Otto
    M. Knauer
    R. Pusch
    N. Harbeck
    Breast Cancer Research and Treatment, 2019, 175 : 389 - 399
  • [4] Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
    Wuerstlein, R.
    Gluz, O.
    Kates, R.
    Persoon, M.
    Wasmayr, M.
    Knauer, M.
    Koplmueller, R.
    Grischke, E-M
    Schem, C.
    Thill, M.
    Hasmueller, S.
    Griesinger, F.
    Koehler, A.
    Otremba, B.
    Schindlbeck, C.
    Reimer, T.
    Krauter, J.
    Tome, O.
    Otto, F.
    Friedrichs, K.
    Albert, U-S
    Gebauer, G.
    Nitz, U.
    Harbeck, N.
    CANCER RESEARCH, 2017, 77
  • [5] IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer
    Soliman, Hatem
    Rehmus, Esther
    Shah, Varsha
    Srkalovic, Gordan
    Mahtani, Reshma
    Levine, Ellis
    Mavromatis, Blanche
    Srinivasiah, Jayanthi
    Kassar, Mohamad
    Gabordi, Robert
    Yoder, Erin
    Qamar, Rubina
    Audeh, William
    CANCER RESEARCH, 2018, 78 (04)
  • [6] MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
    Hatem Soliman
    Varsha Shah
    Gordan Srkalovic
    Reshma Mahtani
    Ellis Levine
    Blanche Mavromatis
    Jayanthi Srinivasiah
    Mohamad Kassar
    Robert Gabordi
    Rubina Qamar
    Sarah Untch
    Heather M. Kling
    Tina Treece
    William Audeh
    BMC Cancer, 20
  • [7] MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
    Soliman, Hatem
    Shah, Varsha
    Srkalovic, Gordan
    Mahtani, Reshma
    Levine, Ellis
    Mavromatis, Blanche
    Srinivasiah, Jayanthi
    Kassar, Mohamad
    Gabordi, Robert
    Qamar, Rubina
    Untch, Sarah
    Kling, Heather M.
    Treece, Tina
    Audeh, William
    BMC CANCER, 2020, 20 (01)
  • [8] Mammaprint and blueprint as prognostic indicators for elderly patients with early stage breast cancer
    Blumencranz, Peter W.
    Habibi, Mehran
    Blumencranz, Lisa
    Menicucci, Andrea
    Wang, Shiyu
    Truitt, Amy
    Audeh, William
    Baginski, Jolanta L.
    Shivers, Steven
    Acs, Geza
    Cox, Charles E.
    CANCER RESEARCH, 2021, 81 (04)
  • [9] WSG BCIST study: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC)
    Wuerstlein, R.
    Sotlar, K.
    Gluz, O.
    Hofmann, D.
    Otremba, B.
    Von Schumann, R.
    Witzel, I.
    Schindlbeck, C.
    Janni, W.
    Schem, C.
    Bauerfeind, I.
    Hasmueller, S.
    Tesch, H.
    Paulenz, A.
    Morel, P.
    Cowens, W.
    Hornberger, A.
    Kates, R. E.
    Pelz, E.
    Harbeck, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 49 - 49
  • [10] MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients
    Haan, Josien C.
    Bhaskaran, Rajith
    Ellappalayam, Architha
    Bijl, Yannick
    Griffioen, Christian J.
    Lujinovic, Ersan
    Audeh, William M.
    Penault-Llorca, Frederique
    Mittempergher, Lorenza
    Glas, Annuska M.
    GENES CHROMOSOMES & CANCER, 2022, 61 (03): : 148 - 160
12345